HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research
NEW HAVEN, Conn., Jan. 19 HistoRx, Inc. announced today that it has appointed Dr. Richard J. Carroll to the newly created position of Vice President, Clinical Research.
Dr. Carroll brings to HistoRx over 20 years of sales, marketing, research, and general management experience in the diagnostic, pharmaceutical and medical device industries. Before joining HistoRx in 2009, he was Vice President of Clinical Research for Cascade Medical Enterprises, a privately-held diagnostics company. Prior to Cascade, Dick held senior positions at Visible Genetics (subsequently acquired by Siemens' Healthcare Diagnostics Group) and Becton Dickinson among other companies. Dick received his Ph.D. in Immunology and Microbiology from the State University of New York and his B.S. in Biology from LeMoyne College.
"I am excited to be part of HistoRx at this pivotal point in its development and ready to lead the expansion of the company's clinical research program, including the establishment of the HistoRx Clinical Trials Network (HCTN)," said Dr. Carroll. He continued, "AQUAŽ technology will be an increasingly important tool in the analysis and validation of clinical biomarkers, as pharmaceutical companies' drug development efforts and the commercialization of new diagnostic products reflect the power of personalized medicine and targeted therapeutics."
Rana K. Gupta, CEO of HistoRx, commented, "Dick's combination of diagnostics industry and product commercialization expertise, and experience with clinical trials, has been of tremendous benefit to the HistoRx management team and will be the keystone of the HistoRx Clinical Trials Network. With Dick's leadership, we will continue to grow our pharmaceutical and biotech relationships and expand our involvement into prospective clinical trials through broader adoption of the AQUAŽ platform in clinical development."
HistoRx has initiated the HCTN in response to specific interest from pharmaceutical companies wanting to use AQUA technology in prospective Phase II and Phase III trials. For the past five years HistoRx's Pharma Services group has used quantitative assessment of multi-biomarker pathways to find solutions to scientific problems posed by pharmaceutical companies and oncology cooperative groups involved in drug discovery, preclinical research and clinical development. These solutions have generated crucial information about customer drug candidates such as the metabolic pathways they affect and the patient subgroups most likely to benefit from them. By increasing HistoRx's capacity to run multiple trials, offer additional analytical technologies and expertise, and bring patient populations to the studies, the HistoRx Clinical Trials Network's comprehensive offerings will expand the customer benefits of these sophisticated tools into late-stage clinical development.
About HistoRx (www.historx.com)
HistoRx, Inc. is a leading developer of tissue-based diagnostic solutions to advance individualized patient care. The company's products and services are based on proprietary analysis of tissue biomarkers using AQUAŽ technology. The AQUAŽ technology is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide drug development and therapeutic decision-making. HistoRx is commercializing a pipeline of proprietary diagnostic products targeting improved treatment decision-making and patient outcomes in cancer care. HistoRx also works with biopharmaceutical companies advance their product pipelines by generating valuable new insights into patient selection, efficacy and safety of therapeutics in development for cancer and other diseases. These partnerships provide the foundation for HistoRx to develop proprietary companion diagnostic tests that HistoRx will co-market with its partners' targeted therapeutics.
SOURCE HistoRx, Inc.
You May Also Like